

665355 P70/008  
Section 29(1)  
Regulation 3.1(2)

**AUSTRALIA**  
*Patents Act 1990*

**NOTICE OF ENTITLEMENT**

I, ALEXANDER GEORGE BRIAN O'NEIL of 200 Churchill Avenue, Subiaco, Western Australia, 6008, Australia, being the applicant in respect of Application No 21663/92 state the following:-

I am the Nominated Person to whom I request the patent to be granted.

The person(s) nominated for the grant of the patent:

has entitlement from the actual inventor(s) by assignment.

The person(s) nominated for the grant of the patent:

has entitlement from the applicant(s) of the application(s) listed in the declaration under Article 8 of the PCT by assignment.

The basic application(s) listed in the declaration made under Article 8 of the PCT

is/are the first application(s) made in a Convention country in respect of the invention

DATED: 2 November 1995

*Gary Nock*

.....  
CARTER SMITH & BEADLE

Patent Attorneys for the Applicant:

**ALEXANDER GEORGE BRIAN O'NEIL**



AU9221663

**(12) PATENT ABRIDGMENT (11) Document No. AU-B-21663/92**  
**(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 665355**

- (54) Title  
**APPARATUS FOR PATIENT-CONTROLLED INFUSION**
- International Patent Classification(s)  
(51)<sup>5</sup> **A61M 005/142**
- (21) Application No. : **21663/92** (22) Application Date : **30.06.92**
- (87) PCT Publication Number : **WO93/00944**
- (30) Priority Data
- | (31) Number   | (32) Date       | (33) Country        |
|---------------|-----------------|---------------------|
| <b>PK6940</b> | <b>01.07.91</b> | <b>AU AUSTRALIA</b> |
| <b>PL2573</b> | <b>25.05.92</b> | <b>AU AUSTRALIA</b> |
- (43) Publication Date : **11.02.93**
- (44) Publication Date of Accepted Application : **04.01.96**
- (71) Applicant(s)  
**ALEXANDER GEORGE BRIAN O'NEIL**
- (72) Inventor(s)  
**ALEXANDER GEORGE BRIAN O'NEIL**
- (74) Attorney or Agent  
**CARTER SMITH & BEADLE , Qantas House, 2 Railway Parade, CAMBERWELL VIC 3124**
- (56) Prior Art Documents  
**WO 91/08002**  
**EP 392566**  
**FR 2588757**
- (57) Claim

1. Apparatus for patient-controlled infusion of a liquid medicament, the apparatus comprising a reservoir for the medicament, a positive displacement pump having a predetermined working volume, a first conduit connecting the reservoir to the pump, a second conduit connected to and extending from the pump and having a distal end to be inserted in the patient, and a one-way valve in the second conduit permitting liquid flow from the pump to the patient and preventing reverse flow; the pump being manually operable to displace liquid through the valve and comprising resilient restoring means for returning the pump to its initial state while drawing liquid from the reservoir through the first conduit; and in which the first conduit has a length in the range 1cm to 40cm and a lumen diameter in the range 0.025mm to 0.20mm whereby the flow rate of liquid medicament through the first conduit is restricted to a rate chosen in conjunction with the working volume of the pump to define a predetermined maximum dosage rate.

OPI DATE 11/02/93 APPLN. ID 21663/92  
 AOJP DATE 08/04/93 PCT NUMBER PCT/GB92/01184



AU9221663

(PCT)

<p>(51) International Patent Classification <sup>5</sup> :  <b>A61M 5/142</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 93/00944</b>          (43) International Publication Date: 21 January 1993 (21.01.93)</p>
<p>(21) International Application Number: PCT/GB92/01184          (22) International Filing Date: 30 June 1992 (30.06.92)          (30) Priority data:              PK 6940                   1 July 1991 (01.07.91)           AU              PL 2573                   25 May 1992 (25.05.92)           AU</p> <p>(71) Applicant (for all designated States except US): <del>PATULLO, Norman</del> [GB/GB]; <del>Mitchell House, 333 Bath Street, Glasgow G2 4ER (GB); 1 Redburn Avenue Giffnock, Glasgow G46 6RH United Kingdom</del>          (72) Inventor; and          (75) Inventor/Applicant (for US only) : O'NEIL, Alexander, George, Brian [AU/AU]; 200 Churchill Avenue, Subiaco, W.A. 6008 (AU).          (74) Agent: MURGITROYD AND COMPANY; Mitchell House, 333 Bath Street, Glasgow G2 4ER (GB).</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p> <p>Published          With international search report.</p>

see folio 4




665355

(54) Title: APPARATUS FOR PATIENT-CONTROLLED INFUSION

(57) Abstract

A reservoir (3) is connected to a manually operable pump such as an aspirating syringe (1) via a flow control tube (4) which has a fine bore of accurately known size. Actuation of the syringe (1) by the patient discharges a fixed volume of drug via a non-return valve (5) to the patient. The syringe (1) is refilled by a return spring (2) drawing liquid from the reservoir (3) at a rate controlled by the bore of the flow control tube (4), thus setting a maximum dosage rate.



1 APPARATUS FOR PATIENT-CONTROLLED INFUSION

2

3 This invention relates to an improved apparatus for  
4 effecting patient-controlled infusion of liquid  
5 medicaments and is particularly, but not exclusively,  
6 applicable to patient-controlled analgesia (PCA).

7

8 It has been recognised for some time that PCA is  
9 desirable in many situations of chronic or temporary  
10 (for example, post operative) pain. Before the advent  
11 of PCA, analgesia relied on periodic injections of  
12 drugs such as synthetic opioids by the physician or  
13 nurse, typically at 4-hour intervals. This has the  
14 disadvantage that for most of the time the patient's  
15 analgesic level is significantly above or below the  
16 optimum.

17

18 PCA improves on that prior art by enabling the infusion  
19 of small quantities of analgesics at regular intervals  
20 as perceived to be required by the patient. However,  
21 to date PCA has been effected by sophisticated  
22 electronic pump systems which have a number of  
23 disadvantages:

24

25 (a) They are expensive.

- b) They are complex and require skilled maintenance.
- c) They are capable of administering an overdose as a result of machine failure or of operator error in setting up; a number of deaths from this cause have been reported.

5

An object of the present invention is to provide an improved PCA apparatus which is simple and inexpensive to manufacture and use, and which has a high level of inherent safety.

The present invention accordingly provides apparatus for patient-controlled  
10 infusion of a liquid medicament, the apparatus comprising a reservoir for the medicament, a positive displacement pump having a predetermined working volume, a first conduit connecting the reservoir to the pump, a second conduit connected to and extending from the pump and having a distal end to be inserted in the patient, and a one-way valve in the second conduit permitting liquid flow from the pump to  
15 the patient and preventing reverse flow; the pump being manually operable to displace liquid through the valve and comprising resilient restoring means for returning the pump to its initial state while drawing liquid from the reservoir through the first conduit; and in which the first conduit has a length in the range 1cm to 40cm and a lumen diameter in the range 0.025mm to 0.20mm whereby the flow rate  
20 of liquid medicament through the first conduit is restricted to a rate chosen in conjunction with the working volume of the pump to define a predetermined maximum dosage rate.

An important preferred feature of the invention resides in the provision of means for introducing a priming liquid into the second conduit without the priming  
25 liquid passing through the first conduit, which means



1 may conveniently comprise a dismountable connection  
2 between the pump and the second conduit whereby the  
3 pump may be removed to allow the second conduit to be  
4 filled with priming liquid through said connection.

5

6 Preferably the pump is a syringe having a plunger  
7 biased outwardly by resilient means.

8

9 The second conduit preferably includes means for  
10 venting gas therefrom, suitably in the form of a filter  
11 which is also capable of removing bacteria.

12

13 In one form of the invention, means are provided for  
14 introducing liquid into the reservoir while the  
15 apparatus is in use, preferably in the form of a third  
16 conduit extending from the reservoir and terminating in  
17 an injection port.

18

19 The third conduit preferably includes a one-way valve,  
20 and may include an air-trapping filter or alternatively  
21 a branch for removing air.

22

23 For safety reasons, the injection port and/or the air  
24 removing branch if present may be provided with  
25 lockable covers.

26

27 The reservoir may suitably comprise a piston and  
28 cylinder or a flexible bag.

29

30 Embodiments of the invention will now be described, by  
31 way of example only, with reference to the drawings in  
32 which:

33

34 Fig. 1 is a schematic view of a PCA apparatus  
35 forming a first embodiment of the invention;

1           Fig. 2 is a schematic view of a second embodiment  
2           containing additional features;

3

4           Fig. 3 is a similar view of a third embodiment  
5           being a modified version of the embodiment of Fig.  
6           2;

7

8           Fig. 4 is a similar view of a further modified  
9           embodiment; and

10

11           Fig. 5 is a perspective view of a practical  
12           embodiment suitable for ambulatory use.

13

14           Referring to Fig. 1, the apparatus comprises a  
15           reservoir in the form of a syringe 3 which is in  
16           communication via a small bore tube 4 with a metering  
17           device in the form of an aspirating syringe 1 whose  
18           plunger 1a is biased upwardly by a return spring 2.  
19           The aspirating syringe 1 is arranged to discharge via a  
20           patient line comprising a one-way valve 5, tubing 6 and  
21           male luer lock connection 9 to an intravenous catheter  
22           secured to the patient. Interposed in the tubing 6 is  
23           a filter 7 of known type for preventing passage of  
24           bacteria and including a hydrophilic membrane 8 which  
25           discharges to atmosphere any air which inadvertently  
26           enters the system. The aspirating syringe 1 can be  
27           connected to and disconnected from the patient line by  
28           means of a connection joint 10.

29

30           In use, the reservoir 3 is filled with a quantity of  
31           analgesic suitable for pain control over a period, for  
32           example 4 hours. Once the system is primed with liquid  
33           and connected to the patient, depression of the plunger  
34           1a causes a quantity of analgesic equal to the volume  
35           of the aspirating syringe 1, typically about 0.5ml, to

1 be infused. When the plunger 1a is released, it  
2 returns under the influence of the spring 2, but at a  
3 rate which is determined by the rate of flow of liquid  
4 from the reservoir 3 through the small bore tube 4.  
5 The overall infusion rate is thus controlled by  
6 suitable selection of the volume of the aspirating  
7 syringe 1 and the flow-resistance of the tube 4 in  
8 relation to a given liquid.

9  
10 The tube 4 is preferably a plastics tube having a very  
11 narrow bore and a relatively thick wall, the latter  
12 ensuring that it does not kink in use. Such a tube and  
13 the method of producing it are described in published  
14 International Patent Application WO88/02637. The tube  
15 4 preferably has a length in the range 1 to 40cm and a  
16 lumen diameter in the range 0.001 inch (0.025mm) to  
17 0.008 inch (0.20mm). In a particularly preferred form,  
18 the lumen diameter is 0.070mm and the tube length 23mm.

19  
20 The use of fine bore tubing not only sets the refill  
21 time of the aspirating syringe 1, but also acts as a  
22 safety factor in inhibiting siphoning of liquid from  
23 the reservoir 3 to the patient. As an additional  
24 safety factor, the one-way valve 5 should have an  
25 opening pressure greater than the maximum possible  
26 hydrostatic pressure which could be present by  
27 elevating the reservoir above the patient to the  
28 maximum height permitted by the length of the tubing.

29  
30 The embodiment of Fig. 2 is similar to that of Fig. 1  
31 and like parts are denoted by like reference numerals.  
32 In this embodiment, the reservoir 3 is provided with a  
33 fill line 20 terminating in an infection site 21 where  
34 the system can be filled or emptied by means of a  
35 standard hypodermic syringe.

1 The embodiment of Fig. 3 is similar to that of Fig. 2,  
2 but the reservoir is in the form of a collapsible bag  
3 30, and the aspirating syringe is replaced by a balloon  
4 31. The balloon 31 is a thick-walled rubber balloon  
5 with sufficient recovery force to draw liquid from the  
6 reservoir 30 through the small bore tube 4.

7  
8 Fig. 4 shows optional features which may be added to  
9 the systems of Figs. 2 and 3. A gas-trapping filter 40  
10 may be included in the fill line 20 to prevent any air  
11 inadvertently introduced at the injection site 21 from  
12 reaching the reservoir 3. Alternatively a branch 41  
13 may be provided, ending in a port 42 for removing from  
14 the system air either introduced inadvertently or at  
15 the initial purging of the system. A one-way valve 45  
16 may be included in the fill line 20 to prevent removal  
17 of liquid from the system.

18  
19 A cover 43 may be placed over the port 42 and secured  
20 in place by a padlock 44 to prevent accidental or  
21 unauthorised use. The cover 43 and padlock 44 may  
22 similarly be used to bar unauthorised access to the  
23 injection site 21.

24  
25 Fig. 5 illustrates one presently preferred, practical  
26 implementation of the invention. Again, like parts are  
27 denoted by like reference numerals. In Fig. 5, the  
28 reservoir syringe 3 is enclosed within a transparent  
29 plastics bag 50 for reasons of safety and hygiene. The  
30 return spring of the aspirating syringe 1 is housed  
31 within a cylindrical casing 51, the plunger being  
32 actuated by a patient demand button 52 extending from  
33 the casing 51. The syringe 1 and the bag 50 are linked  
34 by a cord 53 which allows the apparatus to be hung  
35 around the patient's neck for ambulatory use.

1 An important preferred feature is the ability to remove  
2 the syringe 1 (or equivalent) to assist in priming the  
3 system. The tube 4 has such an extremely fine bore  
4 that it is difficult to force liquid through it from  
5 the reservoir 3 to prime the system, and such a  
6 procedure would take an extremely long time.  
7 Accordingly, to prime the system the aspiration  
8 syringe 1 is removed from the connector 10 and the  
9 patient line is filled with liquid, which may be done  
10 by connecting a relatively large syringe at the  
11 connector 10 and injecting from this to overcome the  
12 resistance of the one-way valve 5. In the case of the  
13 embodiments of Figs 2 to 5, the reservoir fill line is  
14 also primed with liquid at this stage.

15  
16 The aspirating syringe 1 is then re-applied to the  
17 connector 10 with its plunger 1a held down. On release  
18 of the plunger 1a, fluid is drawn through the fine bore  
19 tube 4. This fluid is initially air which becomes  
20 trapped in the syringe 1, but the volume of air  
21 involved (equal to the internal volume of the tube 4)  
22 is so small that it does not affect the operation of  
23 the system.

24  
25 The invention thus provides a patient-controlled  
26 apparatus which is of simple and inexpensive  
27 construction and has a high level of inherent safety.  
28 The apparatus is extremely simple to operate. Owing to  
29 its simplicity and cheapness it can be used as a  
30 disposable item. The apparatus can be manufactured for  
31 use with a particular medicament by suitable choice of  
32 aspirating syringe and bore of the flow control tube;  
33 on-site adjustment is then not required, and the  
34 apparatus can be used by nursing staff without  
35 specialist training who simply have to recharge the

1 reservoir from time to time, suitably by injecting a  
2 single standard 4-hour bolus into the reservoir.

3

4 Although described with particular reference to  
5 patient-controlled analgesia, the invention can be  
6 applied to patient-controlled infusion of other  
7 medicaments such as sedatives and antiemetics.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

The claims defining the invention are as follows :-

1. Apparatus for patient-controlled infusion of a liquid medicament, the apparatus comprising a reservoir for the medicament, a positive displacement pump having a predetermined working volume, a first conduit connecting the reservoir to  
5 the pump, a second conduit connected to and extending from the pump and having a distal end to be inserted in the patient, and a one-way valve in the second conduit permitting liquid flow from the pump to the patient and preventing reverse flow; the pump being manually operable to displace liquid through the valve and comprising resilient restoring means for returning the pump to its initial state while drawing  
10 liquid from the reservoir through the first conduit; and in which the first conduit has a length in the range 1cm to 40cm and a lumen diameter in the range 0.025mm to 0.20mm whereby the flow rate of liquid medicament through the first conduit is restricted to a rate chosen in conjunction with the working volume of the pump to define a predetermined maximum dosage rate.
- 15 2. Apparatus according to Claim 1, including means for introducing a priming liquid into the second conduit without the priming liquid passing through the first conduit.
3. Apparatus according to Claim 2, in which said introducing means comprises a dismountable connection between the pump and the second conduit, whereby the  
20 pump may be removed to allow the second conduit to be filled with priming liquid through said connection.
4. Apparatus according to any preceding Claim, in which the pump is a syringe having a plunger biased outwardly by resilient means.
5. Apparatus according to any preceding Claim, in which the second conduit  
25 includes means for venting gas from the second conduit.



6. Apparatus according to Claim 5, in which the venting means comprises a filter which is also capable of removing bacteria.
7. Apparatus according to any preceding claim, further including means for introducing liquid into the reservoir while the apparatus is in use.
- 5 8. Apparatus according to Claim 7, in which said means for introducing liquid into the reservoir comprises a third conduit extending from the reservoir and terminating in an injection port.
9. Apparatus according to Claim 8, in which the third conduit includes a one-way valve.
- 10 10. Apparatus according to Claim 8 or Claim 9, in which the third conduit includes an air trapping filter.
11. Apparatus according to Claim 8 or Claim 9, in which the third conduit is provided with a branch for removing air.
12. Apparatus according to any preceding claim, in which the reservoir comprises  
15 a piston and cylinder.
13. Apparatus according to any of Claims 1 to 11, in which the reservoir comprises a flexible bag.
14. Apparatus according to any of Claims 8 to 11, in which the injection port is provided with a lockable cover.
- 20 15. Apparatus according to any preceding claim wherein the first conduit has a lumen diameter of about 0.070mm and a length of about 23mm.



16. Apparatus according to any preceding claim, as shown in any one of Figures 1 to 5 of the accompanying drawings.

17. Apparatus substantially as hereinbefore described with reference to and as shown in Fig. 1 or Fig. 2 or Fig. 3 or Fig 4 or Fig 5 of the accompanying drawings.

DATED: 4 August 1995

**CARTER SMITH & BEADLE**

Patent Attorneys for the Applicant:

**NORMAN PATTULLO**

and


**ALEXANDER GEORGE BRIAN O'NEIL**



ONE:PJD:#14757

4 August 1995


1/5



**FIG. 1**


SUBSTITUTE SHEET

2/5



**FIG. 2**


3/5



**FIG. 3**


SUBSTITUTE SHEET

4/5



**Fig. 4**

5/5




**FIG. 5**

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

PCT/GB 92/01184

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61M5/142		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61M	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	WO,A,9 108 002 (PRIME MEDICAL PRODUCTS) 13 June 1991 see page 5, line 11 - page 12, line 5 see figures 1,3	1,7
A	---	2
X	FR,A,2 588 757 (LABORATOIRES PEROUSE) 24 April 1987 see page 1, line 21 - page 3, line 20 see figure 1	1,4,7,13
A	---	5,6
A	US,A,4 187 847 (LOESER) 12 February 1980 see column 3, line 45 - line 61 see figure 1	5,6
A	EP,A,0 392 566 (COOK INC.) 17 October 1990 see column 3, line 1 - line 9 see figure 1	8
	---	
	-/--	
<p><sup>10</sup> Special categories of cited documents:</p> <ul style="list-style-type: none"> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> <li>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>"O" document referring to an oral disclosure, use, exhibition or other means</li> <li>"P" document published prior to the international filing date but later than the priority date claimed</li> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</li> <li>"A" document member of the same patent family</li> </ul>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report:	
27 AUGUST 1992	14. 09. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	SCHOENLEBEN J. 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	GB,A,348 454 (KUNSZTLER) 14 May 1931 see page 2, column 1, line 55 - line 63; figure 2 ---	12
A	WO,A,8 700 758 (BAXTER TRAVENOL LABORATORIES) 12 February 1987 see page 8, line 1 - page 14, line 8 see figure 1 ---	1-4,7,13

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201184  
SA 61474**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 27/08/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9108002	13-06-91	AU-A- 6956991	26-06-91
FR-A-2588757	24-04-87	None	
US-A-4187847	12-02-80	None	
EP-A-0392566	17-10-90	AU-B- 583535	04-05-89
		AU-A- 4811285	10-04-86
		CA-A- 1238830	05-07-88
		EP-A- 0177250	09-04-86
		JP-B- 3060276	13-09-91
		JP-A- 61087565	02-05-86
		US-A- 4687468	18-08-87
GB-A-348454		None	
WO-A-8700758	12-02-87	AU-B- 622514	09-04-92
		AU-A- 4761690	03-05-90
		AU-B- 595540	05-04-90
		AU-A- 6228486	05-03-87
		EP-A- 0231371	12-08-87
		JP-T- 63501195	12-05-88
		US-A- 5061243	29-10-91

EPO FORM P009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82